CNS Pharmaceuticals (NASDAQ:CNSP) is back on every biotech watchlist after a 242.36% one-week ramp tied to its Berubicin glioblastoma story. But here’s what you should actually be watching.
Holders captured the move; new entrants face tougher math from here. The market cap sits at roughly $6.36 million, the company reported a Q1 2024 net loss of $3.50 million with cash collapsed to about $800,000, and the stock is still off 42.18% over one year and effectively 100% over five years on a split-adjusted basis. The defining catalyst, Berubicin topline data, was already telegraphed for the first half of 2025. This week’s move resolves that catalyst rather than anticipating it. Pre-revenue, single-asset, cash-starved binaries carry concentrated risk profiles that compound after a triple-digit week.
The smarter redirects sit in the same central nervous system oncology lane with deeper pipelines, real funding, and commercial traction the crowd has not priced in.
NeOnc Technologies (NASDAQ:NTHI) is the clinical-data redirect. NEO100 in recurrent brain cancer posted a 21% response rate against a historical average below 8%, with 44% of patients reaching six-month progression-free survival versus a 21% to 31% historical band. The FDA cleared NEO212 for Phase II, the NIH layered in $2.5 million of non-dilutive funding, and a $50 million strategic partnership with Quazar Investment opens a Middle East channel through the NuroMENA subsidiary. Patents licensed from USC run to 2038. Shares are down 49.94% year to date, the analyst target stands at $15 against a current quote of $4.14, and the next earnings report lands May 8, 2026.
Plus Therapeutics (NASDAQ:PSTV) is the commercial-traction redirect. The CNSide diagnostic now carries national coverage with UnitedHealthcare and Humana for a combined roughly 67 million covered lives, holds CLIA certification, and is licensed in 49 of 50 states. Plus secured an AMA Category III CPT reimbursement code, a $17.6 million CPRIT grant, and a $3 million DoD pediatric brain cancer grant. ReSPECT-LM data is targeted for Q3 2026 and ReSPECT-GBM for Q4 2026, with management guiding to breakeven by 2027. Q3 2025 EPS came in at -$0.04 against a -$0.70 estimate, a 94.29% beat. The Wall Street average target sits at $38 against today’s $6.30 quote.
A quieter complement to those two oncology names worth researching is Cohen & Steers (NYSE:CNS | CNS Price Prediction) as cash-flow ballast inside a retirement sleeve. Q1 2026 revenue expanded 4.2% YoY to $145.64 million, operating margin reached 34.4%, and global listed infrastructure AUM rose 29.6% YoY to $12.59 billion. The asset manager carries a 3.6% dividend yield, a 23x trailing P/E, and $93.13 billion in AUM with $497 million in net inflows last quarter. The dividend stream offers cash-flow context while the small-cap oncology names work through their volatility cycle.
Biotech is a sector that punishes size and rewards research. Biotech investors weighing the CNSP move can compare it against NTHI’s upcoming clinical data and PSTV’s commercial ramp, both of which sit in the same CNS oncology lane with deeper pipelines and near-term catalysts.
Top Gaining Stocks
Top Losing Stocks